MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication

Executive Summary

• MediciNova announced the publication of a peer‑reviewed article demonstrating that MN‑002, the major metabolite of its investigational compound MN‑001 (tipelukast), markedly enhances cholesterol efflux in macrophages by up‑regulating ABCA1 and ABCG1.
• The findings suggest a novel mechanism for treating atherosclerosis and other metabolic disorders, supporting further clinical investigation of MN‑001 in metabolic disease indications such as dyslipidemia and Type 2 diabetes.
• MediciNova is nearing enrollment completion for its Phase 2 randomized, placebo‑controlled, double‑blind study of MN‑001 in hypertriglyceridemia, Type 2 diabetes, and NAFLD patients.

Key Details

• Publication: Article titled “Enhancement of ABCA1 and ABCG1 Expression and Cholesterol Efflux by a Metabolite of Tipelukast: A Potential Therapeutic Strategy for Atherosclerosis” in Journal of Atherosclerosis and Thrombosis.
• Key Scientific Result: MN‑002 significantly increased cholesterol efflux in macrophages via up‑regulation of transport proteins ABCA1 and ABCG1.
• Therapeutic Implication: Provides mechanistic insight for a potential new treatment approach to atherosclerosis, dyslipidemia, and metabolic disorders.
• Clinical Development Status: Ongoing Phase 2 trial of MN‑001 in hypertriglyceridemia, Type 2 diabetes, and NAFLD; enrollment is nearing completion.
• Company Statement: CEO Yuichi Iwaki highlighted the importance of the mechanistic data and reaffirmed commitment to advancing MN‑001 toward broader metabolic disease indications.

Notable Quotes

“This collaborative research provides the mechanistic insight into how MN‑001 and its metabolite MN‑002 may influence cholesterol and lipid metabolism… We look forward to further clinical investigation in metabolic disease, including dyslipidemia and Type 2 diabetes,” – Yuichi Iwaki, M.D., Ph.D., President & CEO, MediciNova.